Tag «FDA 2014»

DAPAGLIFLOZIN

DAPAGLIFLOZIN, BMS-512148 ダパグリフロジン; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Cas 461432-26-8 Molecular Formula: C21H25ClO6 Molecular Weight: 408.87 Dapagliflozin propandiol monohydrate; 960404-48-2 Molecular Weight 502.98 Formula C21H25ClO6•C3H8O2•H2O Bristol-Myers Squibb (Originator) AstraZeneca TYPE 2 DIABETES,SGLT-2 Inhibitors launched 2012, as forxiga in EU, FDA 2014, JAPAN PMDA 2014 Dapagliflozin propanediol monohydrate was first approved by European Medicine Agency (EMA) on November 12, 2012, then approved by the …

Tasimelteon, タシメルテオン

Tasimelteon N-([(1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide, 609799-22-6 [RN] 8985 Hetlioz [Trade name] N-{[(1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide [ACD/IUPAC Name] Propanamide, N-[[(1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]- [ACD/Index Name] SHS4PU80D9 609799-22-6 cas, BMS-214778; VEC-162, ATC:N05CH03 Use:Treatment of sleep disorder; Melatonin receptor agonist (1R,2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide Formula:C15H19NO2, MW:245.3 g/mol Hetlioz Vanda Pharmaceuticals, 2014 Approved fda 2014 EMA Tasimelteon is a white to off-white crystalline powder, it is non hygroscopic, soluble in water across relevant pH values and freely soluble …

Umeclidinium bromide, ウメクリジニウム臭化物

Umeclidinium bromide GSK-573719A, ウメクリジニウム臭化物 Molecular FormulaC29H34BrNO2 Average mass508.490 Da 1-[2-(Benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1) diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide 7AN603V4JV 869113-09-7 [RN] 9551 GSK573719A; UNII-7AN603V4JV Umeclidinium bromide (trade name Incruse Ellipta) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol).[2][3] In the 2014, the drug was also approved …

VORAPAXAR SULPHATE

VORAPAXAR Thrombosis, Antiplatelet Therapy, PAR1 Antagonists , MERCK ..ORIGINATOR Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester Ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]vinyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(5-(3-fluorophenyl)pyridin-2-yl)ethenyl)- 1-methyl-3-oxododecahydronaphtho(2,3-c)furan-6-yl)carbamate Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(5-(3-fluorophenyl)-2- pyridinyl)ethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-c)furan-6-yl)-, ethyl ester 618385-01-6 CAS NO FREE FORM CAS Number: 705260-08-8 SULPHATE Has antiplatelet activity. Also known as: SCH-530348, MK-5348 Molecular Formula: C29H33FN2O4 Molecular Weight: 492.581723 ZCE93644N2 UNII-ZCE93644N2 Zontivity Registered – 2015 …

DROXIDOPA

DROXIDOPA ORPHAN DRUG, CAS 23651-95-8, 3916-18-5 ROTATION –FORM (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid 223-480-5 [EINECS], L-Tyrosine, β,3-dihydroxy-, (βR)-, L-Tyrosine, β,3-dihydroxy-, threo- Northera [Trade name] threo-b,3-Dihydroxy-L-tyrosine 1-14-00-00685 [Beilstein], L-threo-3-(3,4-Dihydroxyphenyl)serine, L-Dihydroxyphenylserine, L-DOPS;DOPS, \ Northera, SM5688, L-DOPS|Northera®, |SM-5688, L-threo-dihydroxyphenylserine, L-Threodops L-threo-droxidopa, threo-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid THREO-DIHYDROXYPHENYLSERINE threo-Dopaserine UNII:24A0V01WKS UNII:J7A92W69L7 FDA 2/18/2014, FDA approves Northera to treat neurogenic orthostatic hypotension Properties: Crystals from ethanol and ether, mp 232-235° (dec). [a]D20 -39° (c = 1 in 1N …

Naloxegol oxalate

Naloxegol Movantik; NKTR-118; NKTR118; UNII-44T7335BKE; NKTR 118 854601-70-0 cas 1354744-91-4 (Naloxegol Oxalate) (4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol MF C34H53NO11 MW 651.78472 g/mol Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5α,6α)-, ethanedioate (1:1) (salt) Naloxegol oxalate [USAN] UNII-65I14TNM33 AZ-13337019 oxalate Naloxegol (oxalate) NKTR-118 oxalate;AZ-13337019 oxalate UNII:65I14TNM33 Naloxegol oxalate (MovantikTM, Moventig) Naloxegol (INN; PEGylated naloxol;[1] trade names Movantik and Moventig) is a peripherally–selective opioid antagonistdeveloped by …